Ten years after learning their polygenic risk score, patients had fewer events—perhaps due to greater use of statin therapy.

Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...